|
|
Blood, 15 May 2007, Vol. 109, No. 10, pp. 4582-4585.
Prepublished online as a Blood First Edition Paper on February 1, 2007; DOI 10.1182/blood-2006-10-052308.
 Previous Article | Next Article 
Submitted October 20, 2006
Accepted January 24, 2007
Bone marrow transplantation for severe aplastic anemia: a randomized controlled study of conditioning regimens
Richard E. Champlin*, Waleska S. Perez, Jakob R. Passweg, John P. Klein, Bruce M. Camitta, Eliane Gluckman, Christopher N. Bredeson, Mary Eapen, and Mary M. Horowitz
University of Texas M.D. Anderson Cancer Center, Houston, TX, United States
Center for Int'l Blood & Bone Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, United States
Hopitaux Universitaires, Geneva, Switzerland
Medical College of Wisconsin, Milwaukee, WI, United States
Hopital St. Loius, Paris, France
* Corresponding author; email: rchampli{at}mdanderson.org.
The addition of antithymocyte globulin (ATG) to a regimen of high dose cyclophosphamide has been advocated to enhance engraftment after allogeneic bone marrow transplant (BMT) for severe aplastic anemia (SAA). In a prospective clinical trial, 134 patients were randomized to receive cyclophosphamide alone or in combination with ATG. All patients received T-cell-replete bone marrow from an HLA-matched sibling. With a median follow-up of 6 years, the 5-year probabilities of survival were 74% for the cyclophosphamide alone group and 80% for the cyclophosphamide plus ATG group (p=0.44). Graft failure and GVHD rates were similar in both groups. With the survival rates achieved, this study is not adequately powered to detect significant differences between the two treatment groups. In conclusion, the results of allogeneic BMT for SAA have improved over time related to advances in supportive care. The addition of ATG to the preparative regimen did not significantly improve the outcome.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
M. Desmarets, C. M. Cadwell, K. R. Peterson, R. Neades, and J. C. Zimring
Minor histocompatibility antigens on transfused leukoreduced units of red blood cells induce bone marrow transplant rejection in a mouse model
Blood,
September 10, 2009;
114(11):
2315 - 2322.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Maury, A. Bacigalupo, P. Anderlini, M. Aljurf, J. Marsh, G. Socie, R. Oneto, J. R. Passweg, and on behalf of the Severe Aplastic Anemia Working Pa
Improved outcome of patients older than 30 years receiving HLA-identical sibling hematopoietic stem cell transplantation for severe acquired aplastic anemia using fludarabine-based conditioning: a comparison with conventional conditioning regimen
Haematologica,
September 1, 2009;
94(9):
1312 - 1315.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. J. Lee, S. Joffe, A. S. Artz, R. E. Champlin, S. M. Davies, M. Jagasia, N. A. Kernan, F. R. Loberiza Jr, R. J. Soiffer, and M. Eapen
Individual Physician Practice Variation in Hematopoietic Cell Transplantation
J. Clin. Oncol.,
May 1, 2008;
26(13):
2162 - 2170.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Stelljes, S. Hermann, J. Albring, G. Kohler, M. Loffler, C. Franzius, C. Poremba, V. Schlosser, S. Volkmann, C. Opitz, et al.
Clinical molecular imaging in intestinal graft-versus-host disease: mapping of disease activity, prediction, and monitoring of treatment efficiency by positron emission tomography
Blood,
March 1, 2008;
111(5):
2909 - 2918.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Bacigalupo
Aplastic Anemia: Pathogenesis and Treatment
Hematology,
January 1, 2007;
2007(1):
23 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
